Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer.
A group of 20 patients with gastric cancer, refractory to or with no change after two or three cycles of carboplatin were treated with etoposide/folinic acid/5-fluorouracil (ELF). An objective remission rate of 45% (9/20), a median remission duration of 8 months and a median survival time of 11 months were achieved. Toxicities were mild to moderate only. These results are comparable to those being achieved with ELF in previously untreated gastric cancer patients and confirm its efficacy and good tolerability.
Wilke
H
H
Department of Internal Medicine (Cancer Research), Essen University Medical School, Federal Republic of Germany.
Preusser
P
P
Stahl
M
M
Harstrick
A
A
Meyer
H J
HJ
Achterrath
W
W
Schmoll
H J
HJ
Seeber
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D011292:Premedication; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D005047:Etoposide; D016190:Carboplatin; D002955:Leucovorin; D005472:Fluorouracil